№ files_lp_4_process_2_69721
File format: docx
Character count: 8661
File size: 43 KB
Structured briefing package for regulatory consultation including product description, development summary, preclinical and clinical study outlines, and specific questions for FDA discussion.
Year:
2026
Region / City:
United States, Silver Spring, MD
Subject:
Drug and Biologic Product Development
Document Type:
Meeting Package
Organization / Institution:
U.S. Food and Drug Administration (FDA)
Author:
Sponsor Investigator, MD, Professor, Department of University of California, Los Angeles
Target Audience:
FDA Reviewers, CBER/CDER Staff
Submission Date:
2026
Meeting Type:
INTERACT
Product Name:
Biologic XY
Product Description:
Adenoviral vector expressing human cDNA with 1 and 2 region deletions
Proposed Indication:
Treatment or prevention of specific disease or condition
Content Sections:
Introduction, Product Development Summary, Purpose of Meeting, Specific Questions, Supporting Data, Proposed Agenda, Sponsor Attendees, Suggested Dates, Meeting Format, References
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Note:
Year
Subject:
Emergency Use Treatment
Document Type:
Informed Consent Form
Year:
2019
Region / City:
Naas General Hospital
Topic:
Inflammatory Bowel Disease, Biologic Medication
Document Type:
Policy
Author:
Joanna Rea, Inflammatory Bowel Disease Clinical Nurse Specialist
Target Audience:
IBD CNSp, Gastroenterology team, nursing staff administering biologic medication
Approval Date:
14th January 2020
Revision Date:
January 2023
Version Number:
1
Supporting Evidence:
Infliximab, Remicade, Vedolizumab, Adalimumab, Imraldi, Amgevita, Hulio, Golimumab, Ustekinumab
Purpose:
Standardization of pre-screening and management of IBD patients requiring biologic treatment
Scope:
Biologic screening, patient education, IBD CNSp, gastroenterology team, nursing staff
Objective(s):
Ensure best practice for IBD patients on biologics
Outcome(s):
Clarity for staff on safe and evidence-based care for IBD patients on biologics
Governance:
IBD Working Group
Review Group:
Not Applicable
Date of Approval:
14th January 2020
Date of Next Revision:
January 2023
Year:
2025
Region / city:
UK
Topic:
Rheumatology, Axial Spondyloarthritis
Document type:
Guideline
Organization / institution:
British Society for Rheumatology
Author:
Sizheng Steven Zhao, Stephanie R Harrison, Ben Thompson, Max Yates, Joe Eddison, Antoni Chan, Nick Clarke, Nadia Corp, Charlotte Davis, Lambert Felix, Kalveer Flora, William J Gregory, Gareth T Jones, Christopher A Lamb, Helena Marzo-Ortega, Daniel J Murphy, Harry Petrushkin, Virinderjit Sandhu, Raj Sengupta, Stefan Siebert, Danielle A Van Der Windt, Dale Webb, Zenas Z N Yiu, Karl Gaffney
Target audience:
Health professionals, rheumatologists
Period of validity:
Ongoing
Approval date:
2025
Date of changes:
Not specified
Context:
This is a clinical guideline for treating axial spondyloarthritis with biologic and targeted synthetic DMARDs.
Year:
2018
Region / City:
Fredericksburg, VA
Topic:
Biologics, Contracting, Medical Supplies
Document Type:
Contract Award Notice
Agency:
U.S. Department of Veterans Affairs
Author:
Not specified
Target Audience:
Contractors, Veterans Affairs
Period of Action:
From September 27, 2018
Approval Date:
September 27, 2018
Date of Changes:
Not specified
Year:
2021
Region / City:
United States
Topic:
Suitability determination, background checks, child protection
Document Type:
Guidance
Author:
U.S. Department of Justice
Target Audience:
Grant recipients, staff, and volunteers interacting with minors
Period of Validity:
Ongoing
Approval Date:
March 2021
Date of Modifications:
N/A
Year:
2026
Region / State:
Tennessee
District:
Rotary District 6780
Type of document:
Scholarship and award application form
Programs:
James L. Bomar, Jr. Interact Scholarship Award; Fred Brown Interact Award of Merit
Organizing body:
Rotary District 6780
Foundation:
James L. Bomar, Jr., Rotary Interact Scholarship Foundation, Inc.
Submission deadline:
February 17, 2026
Interview location:
Pigeon Forge
Scholarship amount:
$2000 per recipient
Club award amount:
$500 to recipient’s Interact Club
Eligibility:
Members of District 6780 Interact Clubs
Funding source:
District funding and foundation earnings
Tax status:
IRS Section 501(c)(3) tax-exempt foundation
Application requirements:
Transcript, endorsement letters, applicant statement, biography, photo
Year:
201__
Region / City:
District 6970
Topic:
Youth Leadership and Community Service
Document Type:
Ceremony Script
Organization:
Rotary International / Interact Club
Target Audience:
Incoming Interact Club Officers, Rotarians
Period of Activity:
201__ - 201__
Roles Included:
President, Vice-President, Secretary, Treasurer, Directors
Oaths:
Officer Pledge Statements
International Context:
13,009 Interact Clubs, 109 countries
Note:
Year
Topic:
Environmental Science
Document Type:
Educational Material
Target Audience:
Students
Year:
2025
Country:
New Zealand
Education system:
NCEA Level 3
Subject area:
Languages
Language focus:
Lea Faka-Tonga
Standard number:
91681
Credits:
6
Resource title:
Teenage life
Resource reference:
Languages 3.3A v4 Lea Faka-Tonga
Issuing authority:
Ministry of Education
Document type:
Internal assessment resource and guidelines
Target audience:
Secondary school teachers and students
Assessment type:
Internal assessment
Assessment format:
Recorded spoken interactions
Minimum interactions required:
Two
Estimated duration of interactions:
Approximately four to five minutes total
Assessment evidence format:
Digital audio or video recordings
Version:
Version 4
Date version published:
January 2025
Implementation period:
From 2025
Related standard:
Achievement Standard 91683 Write a variety of text types in clear Lea Faka-Tonga to explore and justify varied ideas and perspectives
Resource requirements:
Recording equipment and secure storage of digital recordings
Assessment context:
Discussions related to teenage life in Lea Faka-Tonga
Year:
2016
Region / City:
San Diego, California
Topic:
Event Authorization
Document Type:
Authorization Form
Organization / Institution:
Rotary District 5340
Author:
Not specified
Target Audience:
Parents of students attending the Interact Training Session
Period of Validity:
September 24, 2016
Date of Approval:
Not specified
Date of Modifications:
Not specified
Year:
2016
Region / City:
United States
Topic:
Electronic Informed Consent (eIC)
Document Type:
Guidance
Agency / Institution:
Office for Human Research Protection (OHRP), Food and Drug Administration (FDA)
Author:
Office for Human Research Protection (OHRP), FDA
Target Audience:
Researchers, IRBs, Clinical Investigators, and Study Participants
Period of Validity:
Ongoing
Approval Date:
December 2016
Date of Revisions:
Not specified
Year:
2013–2019
Region:
United States
Subject:
Medical device regulatory submissions
Document type:
Regulatory guidance
Program:
FDA Q-Submission (Q-Sub) Program
Regulatory authority:
U.S. Food and Drug Administration
Centers:
Center for Devices and Radiological Health; Center for Biologics Evaluation and Research
Submission types covered:
Pre-Submission; Submission Issue Request; Study Risk Determination; Informational Meeting
Format requirements:
eCopy
Effective requirement date for eCopy:
January 1, 2013
Final rule date for electronic submissions:
December 13, 2019
Intended audience:
Medical device sponsors and applicants
Scope:
Premarket submissions including IDE, 510(k), PMA, HDE, and De Novo requests
Administrative timeline:
15 calendar days acceptance review; meeting scheduling prior to day 75
Year:
2005
Issuing Organization:
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, Office of In Vitro Diagnostic Device Evaluation and Safety, Division of Immunology and Hematology Devices
Document Type:
Guidance Document
Target Audience:
Industry and FDA Staff
Subject:
AFP-L3% Immunological Test Systems, In Vitro Diagnostic Devices, Class II Special Controls
Date Issued:
October 4, 2005
Contact:
Donna Roscoe, [email protected]
Note:
, 301-796-6183
Year:
2023
Region / City:
Duke University
Theme:
Medical Device Regulation
Document Type:
Instructional Document
Organization / Institution:
Duke Office of Regulatory Affairs and Quality
Author:
Duke University
Target Audience:
Medical device developers, regulatory affairs professionals
Period of validity:
N/A
Approval Date:
N/A
Modification Date:
N/A
Note:
Year
Target Audience:
Principal Investigators and study team members
Purpose:
This template may be used to record and track regulatory documents for human subject research clinical trials with Investigational Product (IP) not under an FDA IND/IDE
Study-related documents:
IRB approval documents, DSMB correspondence, NIMH grant-related documents, Study Staff training, Investigational Product documentation
Context:
A regulatory checklist for managing essential documents required in human subject research clinical trials with an investigational product not under an FDA IND/IDE.
Note:
Year
Topic:
Health, Pharmaceuticals
Document Type:
Informational Resource
Organization / Institution:
U.S. Food and Drug Administration
Target Audience:
Consumers, Healthcare Providers, Information Professionals, Researchers
Year:
2025
Region / city:
Massachusetts
Subject:
Tobacco product sales regulations
Document type:
Guidance Document
Organization / institution:
Massachusetts Association of Health Boards
Author:
Cheryl Sbarra, Esq., Executive Director and Senior Staff Attorney, Massachusetts Association of Health Boards; Christohper Banthin, Esq., Program Manager, Public Health Advocacy Institute; Lisa Stevens-Goodnight, Esq., Tobacco Control Director, Massachusetts Municipal Association; Sarah McColgan, Tobacco Control Director, Massachusetts Health Officers Association
Target audience:
Tobacco retailers and permit applicants
Effective period:
2025
Approval date:
12.30.25
Date of changes:
N/A
Year:
2021
Region / city:
United States
Topic:
Drug and Biologic Submission Forms
Document Type:
Regulatory Document
Organization:
U.S. Food and Drug Administration (FDA)
Author:
Center for Drug Evaluation and Research (CDER), Center for Biologic Evaluation and Research (CBER)
Target Audience:
Pharmaceutical industry professionals, regulatory submission staff
Effective Period:
2021 and onwards
Approval Date:
Not specified
Modification Date:
Not specified
Date:
December 1, 2025 - January 27, 2026
Region / city:
USA
Topic:
Research oversight, FDA guidance updates
Document type:
Regulatory update
Institution:
FDA
Target audience:
Research professionals, oversight committees, investigators, research organizations
Period of validity:
December 1, 2025 - January 27, 2026
Approval date:
December 1, 2025
Modification date:
January 27, 2026
Year:
2018
Jurisdiction:
Rwanda
Document type:
Regulation
Governing body:
Rwanda Food and Drugs Authority (Rwanda FDA)
Approval date:
09/02/2018
Revision date:
11/08/2025
Version:
1
Scope:
Processed food products and related items
Articles:
64
Chapters:
7
Regulated activities:
Manufacturing, licensing, inspection, import/export, registration, promotion, advertisement
Applicable standards:
GMP, GSP, GDP